Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 5Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Oropharyngeal Neoplasms 2Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 67Leucovorin 61Oxaliplatin 49Irinotecan 31Capecitabine 23Cetuximab 22Bevacizumab 20Folfox protocol 13Radiotherapy 12Chemotherapy, Adjuvant 11Neoadjuvant Therapy 10Erlotinib Hydrochloride 7dehydroftorafur 5Trastuzumab 5Radiation 5Melphalan 5Magnetic Resonance Spectroscopy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5sargramostim 4Sigmoidoscopy 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Gene Expression Profiling 4Gefitinib 4Floxuridine 4Biopsy 4aldesleukin 3Sorafenib 3Semaxinib 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rectal Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡